Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (b) As previously announced by the Company on February 23, 2024, Sarah Friar will resign from her position as the Chief Executive Officer, and President and Chairperson of the Board of Directors (the “Board”) of the Company. The transition will be effective May 8, 2024 (the “Transition Date”). On February 24, 2024, the Board approved a decrease in the authorized number of directors from nine to eight, effective as of the Transition Date. Ms. Friar’s planned departure is not a result of any disagreement regarding the Company’s operations, policies or practices. In connection with her transition, the Company is expected to enter into a Transition Agreement with Ms. Friar (the “Transition Agreement”), which provides for the following benefits: (i) a lump sum payment equal to six months’ base salary, less applicable state and federal payroll deductions, and (ii) upon her election to continue her existing health benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, the Company paying the insurance premium payments for Ms. Friar to continue to receive coverage for twelve months following the Transition Date. The Transition Agreement includes a general release of claims in favor of the Company. The foregoing description of the Transition Agreement is qualified in its entirety by reference to the text of the Transition Agreement, which will be filed as an